Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance.
The purpose of the present study was to model the effects of the concentration of Eudragit L 100 and compression pressure as the most important process and formulation variables on the in vitro release profile of aspirin from matrix tablets formulated with Eudragit L 100 as matrix substance and to optimize the formulation by artificial neural network. As model formulations, 10 kinds of aspirin matrix tablets were prepared. The amount of Eudragit L 100 and the compression pressure were selected as causal factors. In vitro dissolution time profiles at 4 different sampling times were chosen as responses. A set of release parameters and causal factors were used as tutorial data for the generalized regression neural network (GRNN) and analyzed using a computer. Observed results of drug release studies indicate that drug release rates vary widely between investigated formulations, with a range of 5 hours to more than 10 hours to complete dissolution. The GRNN model was optimized. The root mean square value for the trained network was 1.12%, which indicated that the optimal GRNN model was reached. Applying the generalized distance function method, the optimal tablet formulation predicted by GRNN was with 5% of Eudragit L 100 and tablet hardness 60N. Calculated difference (f1 2.465) and similarity (f2 85.61) factors indicate that there is no difference between predicted and experimentally observed drug release profiles for the optimal formulation. This work illustrates the potential for an artificial neural network, GRNN, to assist in development of extended release dosage forms.
Ibrić
Svetlana
S
Institute of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy, University of Belgrade, Serbia and Montenegro. ibric@beotel.yu
Jovanović
Milica
M
Djurić
Zorica
Z
Parojcić
Jelena
J
Petrović
Slobodan D
SD
Solomun
Ljiljana
L
Stupar
Biljana
B
D001241:Aspirin / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D015195:Drug Design; D016571:Neural Networks, Computer; D011109:Polymethacrylic Acids / Q000737:chemistry*; D013607:Tablets
D003692:Delayed-Action Preparations; D011109:Polymethacrylic Acids; D013607:Tablets; C038300:methylmethacrylate-methacrylic acid copolymer; D001241:Aspirin